Our Mission

To discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye.

Who is Tarsus?

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions where there are limited treatment alternatives. We are advancing our pipeline to address a number of diseases across therapeutic categories including eye care, dermatology, and other diseases with high unmet needs.

Our flagship product, TP-03, has the potential to be the first FDA-approved therapeutic and the standard of care for the treatment of Demodex blepharitis.

Learn about Demodex blepharitis

Demodex blepharitis

Blepharitis is a common ocular condition that is characterized by inflammation of the eyelid and affects up to 20 million Americans; Demodex mites cause approximately 45% of these cases in the United States.1-5

Population Epidemiology1-5
(based on 20M in US with blepharitis)
55%

without Demodex infestation

45%

with Demodex infestation


That means there are approx.
9 million patients without an FDA-approved therapy.1-5

We believe that number may be even higher than what’s been previously reported

Published literature shows that at least 45 million people visit eye care clinics annually. Our internal research has shown that 58% of patients presenting at eye care offices have collarettes, a pathognomonic sign of Demodex infestation.

We believe that the prevalence of Demodex blepharitis in the United States may be as high as ~25 million.

Learn how Demodex mites cause disease

Demodex blepharitis is caused by infestation of Demodex mites, the most common ectoparasite found on humans. There are two species of Demodex—folliculorum and brevis—that live on the skin of the face and eyelids.

Demodex
folliculorum

Demodex
brevis

What is TP-03?

TP-03 is a novel therapeutic that may offer treatment, if approved, for millions of patients with Demodex blepharitis.

Every year, a projected ~1 million patients are diagnosed with Demodex blepharitis and left without an FDA-approved treatment. TP-03 can change that.

  • Designed to paralyze and eradicate mites and other parasites through the inhibition of parasite-specific GABA-Cl channels
  • Has completed four Phase 2 trials in Demodex blepharitis, all of which met their respective endpoints
  • Well-tolerated with no significant adverse events leading to treatment discontinuation across the four trials
  • Has begun pivotal Phase 2b/3 trial and has the potential to be the first FDA-approved therapeutic and standard of care for the treatment of Demodex blepharitis
468708027
Clinical Summary: Mars Study

Presented by Roberto Gonzalez-Salinas, M.D., Ph.D. at ARVO 2020 Virtual Meeting.

468708553
Clinical Summary: Mars and Jupiter Studies

Presented by Paul Karpecki, OD, FAAO at AAOPT 2020 Virtual Meeting.

468709092
Clinical Summary: Io and Europa Studies

Presented by Roberto Gonzalez-Salinas, M.D., Ph.D. on October 6, 2020.

Expert Leadership

Bobak Azamian, M.D., Ph.D.
Chief Executive Officer

Bobby is co-founder and CEO of Tarsus. He has co-founded…

Read More

Bobby is co-founder and CEO of Tarsus. He has co-founded and built three companies advancing pioneering chronic disease treatments; provided leadership and strategic guidance through discovery, development, and commercialization; and raised over $150M from institutional investors and corporate partners. Bobby previously served as CEO and Chief Medical Officer of Metavention. He also serves on the boards of Vibrato Medical and the nonprofit Octane.

Bobby began his biotechnology career as an investor and entrepreneur with Versant Ventures and Third Rock Ventures. He previously completed a residency in internal medicine and was an attending hospitalist at Brigham and Women’s Hospital. He received an M.D. from Harvard Medical School (Harvard-MIT Health Sciences and Technology), a Ph.D. in chemistry from Oxford University as a Rhodes Scholar, and a B.A. in physics from Rice University.

Michael Ackermann, Ph.D.
Chairman

Michael is a co-founder and Chairman of the Board of Tarsus…

Read More

Michael is a co-founder and Chairman of the Board of Tarsus. He also serves as Chairman of Oyster Point Pharma, Inc. (NASDAQ: OYST) and Presidio Medical, Inc. He was previously Vice President, Neurostimulation for Allergan plc after serving as CEO of Oculeve, Inc., which was acquired by Allergan. He received a B.E. degree in biomedical engineering from Vanderbilt University and M.S. and Ph.D. degrees in biomedical engineering from Case Western Reserve University. He is a graduate of Stanford University’s Biodesign Fellowship and Vision Research Fellowship. He has numerous patents and peer-reviewed publications.

Leo Greenstein
Chief Financial Officer

Leo has more than 20 years of business experience within…

Read More

Leo has more than 20 years of business experience within the life sciences and technology sectors. Prior to joining Tarsus, he was Senior Vice President of Finance & Corporate Controller at Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), where he was responsible for leading all aspects of their financial planning and analysis, treasury management, accounting operations, stock-plan administration, tax planning and compliance, and SEC reporting. He has played significant roles in the assessment and completion of numerous capital raises as well as investor relations and business development activities. In addition, he has recruited and developed high-performing accounting and finance teams in the U.S. and Europe; designed business processes that are efficient, scalable, and SOX compliant; and implemented a variety of IT systems that have enhanced finance and accounting capabilities.

Prior to joining Spectrum in 2013, Leo served as Vice President of Finance & Corporate Controller with Endologix, Inc. (NASDAQ: ELGX); Senior Director of Finance at Clarient, Inc. (NASDAQ: CLRT), which was acquired by GE Healthcare in December 2010; and assistant controller at Safeguard Scientifics, Inc. (NYSE: SFE).

He earned his B.A. in accounting from Arcadia University in Glenside, Pennsylvania and his J.D. from Temple University. He is a Certified Public Accountant (license active in California) and a member of the State Bar of California.

Aziz Mottiwala
Chief Commercial Officer

Aziz has over 20 years of leadership experience in the…

Read More

Aziz has over 20 years of leadership experience in the biopharmaceutical industry, across all areas of commercialization in several therapeutic areas, including over 10 years in the eye care space. Prior to joining Tarsus, Aziz was Chief Commercial Officer at Opiant Pharmaceuticals, overseeing all aspects of commercial strategy for the company’s portfolio in addiction medicine. Prior to that, he was Senior Vice President and Head of Commercial at Avanir Pharmaceuticals. He also spent over 10 years at Allergan, most recently as Vice President of Marketing for the company’s eye care franchise. While at Allergan, he helped grow the eye care business to over $2 Billion in revenue across a diverse portfolio that included products like RESTASIS®, LUMIGAN®, and several other devices, including the OTC product lines. Earlier in his career, Aziz held various commercial leadership roles at Valeant, IMS Health (now IQVIA), and Aventis Pharmaceuticals (now Sanofi). He received a B.S. in biochemistry from the University of California San Diego and an MBA in marketing and finance from the Marshall School of Business at the University of Southern California. He is also heavily active in the community and serves on the board of the Orange County nonprofit OneOC.

Sesha Neervannan, Ph.D.
Chief Operating Officer

Sesha has over 25 years of experience with the global drug development…

Read More

Sesha has over 25 years of experience with the global drug development of novel therapeutics. Prior to joining Tarsus, he was a Senior Vice President of Global Pharmaceutical Development at Allergan, where he built strong and nimble early development functions to rapidly enable proof of concept as well as a robust late-stage development organization for product approval and commercialization of small molecules and biologics. He also established an industry-leading expertise in ocular drug delivery technologies through his oversight of and contribution to multiple ocular, oral, and dermal product development programs, regulatory filings, and approvals, including novel intraocular, sustained-release injectables (Ozurdex®, Durysta®), a multidose non-preserved drug product in a novel container-closure delivery system (Restasis MultiDose®), topical dermal products (Rhofade® Cream, Aczone® Gel 7.5%), and several Rx and OTC topical ophthalmic products. Additionally, he has received recognition for inspiring high-performing teams and translating strategy into results-driven objectives with a focus on people development.

Prior to joining Allergan in 2007, Sesha was Director, Pharmaceutics R&D at Amgen Inc., where he oversaw CMC functions and assisted in building pharmaceutics functions, primarily focusing on a discovery-development interface to enable pipeline advancement. Early in his career, he was Senior Research Investigator, Pharmaceutics R&D at Bristol-Myers Squibb Pharmaceutical Research Institute.

Sesha has a Ph.D. in pharmaceutical chemistry, with honors, from the University of Kansas and a B.S. in pharmacy, with honors, from Birla Institute of Technology and Science, Pilani, India.

Elizabeth Yeu, M.D.
Chief Medical Advisor (consultant)

Elizabeth earned her medical degree through an accelerated…

Read More

Elizabeth earned her M.D. through an accelerated and combined undergraduate/medical school program at the University of Florida College of Medicine. She completed her ophthalmology residency at Rush University Medical Center in Chicago, where she served as Chief Resident (2006-2007). She continued to the Cullen Eye Institute, Baylor College of Medicine to complete a fellowship in cornea, anterior segment and refractive surgery (2007-2008), where she served as an assistant professor. She then joined Virginia Eye Consultants in 2013 and has been a partner since 2014. She also continues to train residents as an assistant professor at the Eastern Virginia Medical School.

Elizabeth has authored hundreds of articles and is a frequent lecturer nationally and internationally in the areas of refractive cataract surgery, anterior segment reconstruction, and external disease management. She provides guidance and governance across several national medical boards and committees, including as an examiner for the American Board of Ophthalmology and as the Chair of the Cataract Section of Ophthalmic News & Education (ONE) Network for the American Academy of Ophthalmology (AAO). She is an Executive Committee member and is the current Secretary for the American Society of Cataract and Refractive Surgery (ASCRS). In 2023, she will become President of the ASCRS.

Mark Holdbrook
VP, Clinical Affairs

Mark has over 40 years of experience in the design, execution, analysis…

Read More

Mark has over 40 years of experience in the design, execution, analysis, and reporting of clinical trials. He has experience in epidemiology as well as in the medical device, biotechnology, and pharmaceutical industries. His therapeutic areas of expertise include ophthalmology, cardiology, oncology, orthopedics, gynecology, and dermatology. Most recently, he was the Senior Director of Clinical Affairs and Biostatistics at Oculeve, Inc., where he led the successful clinical development of the TrueTear® device. Prior to Oculeve, he was the Vice President of Clinical Affairs, Data Management and Biostatistics for Experien Group, LLC, a medical device consulting firm. He also spent 10 years at Santen, Inc. in various positions developing ophthalmic pharmaceuticals.

Mark holds a B.A. from the University of California at San Diego.

Kim Norman
Sr. Director, Finance

Kim has more than 12 years of business experience within the life sciences…

Read More

Kim has more than 12 years of business experience within the life sciences sector. Prior to joining Tarsus, she was Director, Corporate Finance and Accounting at Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), where she was responsible for their financial planning & analysis, accounting operations, board and SEC reporting, and various IT system implementations to enhance finance and accounting capabilities.

Prior to joining Spectrum in 2013, Kim served as FP&A Manager with Endologix, Inc. (NASDAQ: ELGX), a medical device company that specializes in stent grafts and accompanying delivery systems for the treatment of abdominal aortic aneurysms.

Kim began her career in public accounting with PricewaterhouseCoopers LLP. She earned her B.S. in accounting from the University of Arizona in Tucson, Arizona and is a Certified Public Accountant (license active in California).

Stephanie Baba, O.D., F.A.A.O.
Director, Clinical Affairs

Stephanie is an experienced Director of Clinical Affairs…

Read More

Stephanie is an experienced Director of Clinical Affairs with a demonstrated history of working in the pharmaceutical and medical device industries. Formerly, she practiced as an optometrist in many clinical settings throughout the San Francisco Bay Area, including in optometric and ophthalmologic private practices. She served on the clinical faculty of the University of California at Berkeley School of Optometry for over 15 years. Stephanie is a Fellow of the American Academy of Optometry and has served on committees of the American Optometric Association Contact Lens and Cornea Section, as President of the Alameda-Contra Costa Counties Optometric Society, and on the board of the Berkeley Optometry Alumni Association. Additionally, she has authored numerous peer-reviewed manuscripts on anterior segment diseases.

Shawn Hickok
Director, Pharmaceutical Sciences

Shawn has extensive experience in both the development and commercialization…

Read More

Shawn has extensive experience in both the development and commercialization of ophthalmic and injectable pharmaceutical dosage forms. Most of his 38 years of experience have been in producing NCE, OTC, and generic products. His work experience spans from Scientist to Director positions at Allergan (14 years), Akorn (3 years), and Santen Inc/Ltd (15 years). Prior to joining Tarsus, Shawn established BOT Pharma, where he has been using cartesian robotics to screen formulations for the last 6 years.

Shawn holds a B.S. degree in chemistry from the University of California and has completed an extensive material sciences degree program at Hokkaido University in Sapporo, Japan.

Maáza Martin
Director, Marketing

Maáza has over 13 years of experience in marketing, strategic…

Read More

Maáza has over 13 years of experience in marketing, strategic consulting, and analytics in the pharmaceutical industry. Prior to joining Tarsus, Maáza was Senior Manager of Strategic Marketing at Avanir, where she led a cross-functional commercialization team responsible for the launch readiness of a CNS product expected to be the first-ever therapy for agitation in patients with Alzheimer’s dementia. Prior to that, during her time at Allergan, Maáza served as the Marketing Account lead on Restasis® for over 6 years; in this role, she developed and executed the competitive strategy prior to the launch of Xiidra® and helped drive the brand to its sustained blockbuster status. She was also instrumental in the go-to-market strategy and launch of TrueTear®, a neurostimulation device for dry eye that was developed by Oculeve, Inc. Prior to her time at Allergan, Maáza worked in the Market Analysis and Strategy group at Genentech and was a Senior Consultant at IMS Health (now IQVIA).

Maáza holds M.S. and B.A. degrees in bioengineering from Dartmouth College and certification from the Business Bridge Program at the Tuck School of Business.

Steven Reyes
Director, Project Management

Steven has 16 years of experience in the pharmaceutical industry…

Read More

Steven has 16 years of experience in the pharmaceutical industry driving the development of novel therapeutics from ideation to commercialization in ophthalmology, urology, and oncology. Prior to joining Tarsus, he was an Associate Director of Project Management at Allergan, where he led several cross-functional teams developing numerous ophthalmic assets. While at Allergan, Steven played an integral role in leading the development, submission, and subsequent approval of the first-in-class intracameral sustained-released implant for glaucoma (DURYSTA®). Before joining Allergan, he was the Director of Portfolio and Project Management at Metagenics, where he established a PMO to drive the advancement and commercialization of numerous healthcare products. Early in his career, Steven held various roles in PK/PD, toxicology, and clinical research. He is a certified Project Management Professional (PMP®) and holds a B.S. in pharmacology from the University of California, Santa Barbara and an MBA from Pepperdine University.

Michael Ackermann, Ph.D.
Chairman

Michael is a co-founder and Chairman of the Board of Tarsus.

Read More

Michael is a co-founder and Chairman of the Board of Tarsus. He also serves as Chairman of Oyster Point Pharma, Inc. (NASDAQ: OYST) and Presidio Medical, Inc. He was previously Vice President, Neurostimulation for Allergan plc after serving as CEO of Oculeve, Inc., which was acquired by Allergan. He received a B.E. degree in biomedical engineering from Vanderbilt University and M.S. and Ph.D. degrees in biomedical engineering from Case Western Reserve University. He is a graduate of Stanford University’s Biodesign Fellowship and Vision Research Fellowship. He has numerous patents and peer-reviewed publications.

Bobak Azamian, M.D., Ph.D.
Chief Executive Officer

Bobby is co-founder and CEO of Tarsus and Co-Chairman of Vibrato Medical.

Read More

Bobby is co-founder and CEO of Tarsus and Co-Chairman of Vibrato Medical. He has co-founded and built three companies advancing pioneering chronic disease treatments; provided leadership and strategic guidance through discovery, development, and commercialization; and raised over $150M from institutional investors and corporate partners. Bobby previously served as CEO and Chief Medical Officer of Metavention. He also serves on the board of the nonprofit Octane.

Bobby began his biotechnology career as an investor and entrepreneur with Versant Ventures and Third Rock Ventures. He previously completed a residency in internal medicine and was an attending hospitalist at Brigham and Women’s Hospital. He received an M.D. from Harvard Medical School (Harvard-MIT Health Sciences and Technology), a Ph.D. in chemistry from Oxford University as a Rhodes Scholar, and a B.A. in physics from Rice University.

Bhaskar Chaudhuri, Ph.D.
Director

Bhaskar joined Frazier Healthcare Partners in 2011 as Operating Partner.

Read More

Bhaskar joined Frazier Healthcare Partners in 2011 as Operating Partner. He brings significant operational experience in drug research, development, and commercialization in the United States, Europe, and emerging markets to the Life Science team. He also leads investments in later-stage companies as well as in international opportunities and is a co-founder of Arcutis (NASDAQ: ARQT), where he currently serves on the board. Bhaskar also serves on the board of Teligent (NASDAQ: TLGT) and is an advisor to the Johns Hopkins Berman Institute of Bioethics. He also served on the boards of directors of Silvergate Pharmaceuticals (acquired by CutisPharma), Corium International (acquired by Gurnet Point Capital), and Thesan Pharmaceuticals.

Prior to joining Frazier, Bhaskar was President of Valeant Pharmaceuticals, where he led Valeant’s international operations and business development activities. He joined Valeant through its acquisition of Dow Pharmaceutical Sciences, where he had been President and CEO. Before Dow, Bhaskar worked at Mylan Pharmaceuticals in several capacities including EVP of Scientific Affairs at Bertek Pharmaceuticals, a Mylan subsidiary, and as General Manager of the Dermatology Division. Earlier, he worked at Penederm, a skincare and drug-delivery company, as VP of R&D.

Bhaskar holds a Ph.D. in pharmaceutics, an M.S. in industrial pharmacy, and a B.S. in pharmacy.

Andrew Goldberg, M.D.
Director

Andrew is a Principal at Palo Alto-based Vivo Capital, where he helps lead investments…

Read More

Andrew is a Principal at Palo Alto-based Vivo Capital, where he helps lead investments in private pharmaceutical and medical device companies across all life-cycle stages. Prior to Vivo, he worked at McKinsey & Company in their Silicon Valley office, where he served global pharmaceutical, medical device, and biotechnology companies across a range of strategy, M&A, sales, marketing, and product development topics. He currently serves or has served on the board of several life sciences companies including Swift Health Systems Inc (Chairman), Arcutis Biotherapeutics (ARQT) (observer), Instil Bio (observer), Harmony Biosciences (observer), and Impel Neuropharma (observer). His other representative investments include Rivervision (acquired by Horizon) and Tricida (TCDA).

He is a U.S. board-certified physician in both critical care medicine and emergency medicine. He has served as an instructor in medicine at the Mayo Clinic College of Medicine in Rochester, MN, where he completed a fellowship in critical care medicine and served as an attending physician in the Department of Emergency Medicine. Prior to this, he completed a emergency medicine residency training at Los Angeles County + University of Southern California Medical Center (LAC+USC).

He received his M.D. from The George Washington University School of Medicine in Washington, DC, and has held academic and clinical appointments at the Stanford VA Palo Alto Medical Center, Oregon Health & Science University, the University of Arizona, and currently, Washington Township Medical Foundation.

William J. Link, Ph.D.
Director

Bill is Founder and Managing Partner of Flying L Partners and a Founder and Managing Director…

Read More

Bill is Founder and Managing Partner of Flying L Partners and a Founder and Managing Director of Versant Ventures. He has over two decades of operations experience in the healthcare industry and specializes in early-stage investing in medical devices. Prior to co-founding Versant Ventures, Bill was a general partner at Brentwood Venture Capital. He was previously Founder, Chairman, and CEO of Chiron Vision, which was sold to Bausch and Lomb in 1997. Prior to Chiron Vision, Bill founded and served as President of American Medical Optics (AMO), a division of American Hospital Supply Corporation, which was sold to Allergan in 1986. Later, he served on the board of AMO’s successor company, Advanced Medical Optics (AMO), which was acquired by Abbott in 2009 and then by Johnson and Johnson in 2016. Before entering the healthcare industry, he was an assistant professor in the Department of Surgery at the Indiana University School of Medicine. Bill currently serves on the boards of several private companies as well as of Edwards Lifesciences (NYSE: EW), Glaukos (NYSE: GKOS), and Oyster Point Pharma, Inc. (NASDAQ: OYST). He received his B.S., M.S., and Ph.D. from Purdue University.

Jason Tester
Director

Jason is the Chief Financial Officer of the Horowitz Group, an opportunistic…

Read More

Jason is the Chief Financial Officer of the Horowitz Group, an opportunistic, multi-asset class family investment office in Newport Beach, California. His notable transactions include the ownership and sale of Standard Concrete and founding investments in Sprouts Farmers Markets and Lemonade, a fast-casual dining concept. In addition to his CFO responsibilities, Jason is active in the firm’s healthcare transactions. His recent healthcare investments include Metavention, a medical device company developing a novel glucose control therapy for patients with Type 2 diabetes, and Tarsus Pharmaceuticals. Prior to Horowitz Group, Jason served for 9 years as the CFO of AcuFocus, an ophthalmic medical device company focused on solutions for presbyopia. Previously, Jason worked in investment banking at Jefferies and BNP Paribas, with a concentration in healthcare, and also worked in business development for the Innovation Factory, a medical device incubator. Jason began his career as a Certified Public Accountant; he holds an MBA from Emory University, a Master of Accountancy specializing in Tax, and a bachelor’s degree in business administration from the University of Georgia. Jason is married with three children and serves on the board and as Treasurer of Mariners Christian School.

Wendy Yarno
Director

Wendy has more than 30 years of experience in the biopharmaceutical industry…

Read More

Wendy has more than 30 years of experience in the biopharmaceutical industry, as a public company director and product commercialization leader, including 26 years at Merck & Co. Inc.

While at Merck, Wendy held positions of increasing seniority, most recently as Chief Marketing Officer. In that position, she led a global organization charged with all aspects of commercialization of pharmaceuticals in more than 20 therapeutic areas. She also served as General Manager, Cardiovascular/Metabolic U.S. Business Unit, and as Merck’s Senior Vice President of Human Resources. Earlier in her career, she was Vice President of the Women’s Health Care franchise for Johnson & Johnson’s Ortho-McNeil Pharmaceutical subsidiary.

Wendy has served on the boards of several public and private biotechnology and medical device companies, including St. Jude Medical, Medivation, Alder Biopharmaceuticals, Aratana Therapeutics, and Myokardia. She currently serves on the boards of Global Blood Therapeutics, Ideaya Biosciences, and Inovio Pharmaceuticals. Wendy received a B.S. in business administration from Portland State University and an M.B.A. from Temple University, Fox School of Business.

News

11/19/2020
Tarsus Pharmaceuticals, Inc. Appoints Wendy Yarno to Board of Directors

Read More

11/13/2020
Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference

Read More

10/20/2020
Tarsus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise by the Underwriters of Option to Purchase Additional Shares

Read More

10/15/2020
Tarsus Pharmaceuticals Inc. Announces Pricing of Initial Public Offering

Read More

10/06/2020
Tarsus Releases Data from Io and Europa Trials for TP-03 to Treat Demodex Blepharitis and Begins Enrollment and Treatment in Phase 2b/3 Saturn-1 Trial

Read More

08/11/2020
Tarsus Pharmaceuticals Welcomes Aziz Mottiwala as Chief Commercial Officer and Relocates to Larger Irvine Headquarters

Read More

07/16/2020
Tarsus Pharmaceuticals Announces Appointment of New COO and CFO

Read More

06/15/2020
Tarsus Pharmaceuticals Announces Positive Results of the Mars study, a Phase 2a Study of the Efficacy and Safety of TP-03 to Treat Demodex Blepharitis, at ARVO 2020 Virtual Meeting

Read More

01/08/2020
Tarsus Pharmaceuticals Raises $60 Million in Series B Financing

Read More

More News

References: 1. MGD Report IOVS, Special Issue 2011, Vol. 52, N. 4; 2. American Optometric Association; 3. Primary Care Optometry News, February 1997; 4. IOVS June 2020; 5. Zhao -Ophthalmic Epidemiology, 19(2), 95–102, 2012; 6. Wilson J Ophthalmology 2015, 435606, 2014; 7. Tarsus collarette prevalence study.